Yijia Hua

Suzhou Municipal Hospital — China

Medicine · Health Sciences

10h-index329citations48works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(14), HER2/EGFR in Cancer Research(13), Cancer-related Molecular Pathways(9), Cancer, Hypoxia, and Metabolism(8), RNA modifications and cancer(8)

Publications48 total

Integrated Biomimetic Platform for Enhancing the Efficient Capture and Visual Identification of Circulating Tumor Cells
Analytical Chemistry·2025
m6A mRNA methylation initiated by METTL14 promotes STK11 translation and increases STK11 activity to induce anti-HER2 therapy resistance in breast cancer
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease·2025
An open‐label phase <scp>II</scp> study: The efficiency and safety of anlotinib + eribulin in patients with <scp>HER2</scp> ‐negative metastatic breast cancer
International Journal of Cancer·2025· 1 cited
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer
eLife·2025· 5 citedOpen Access
Author response: Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer
2025Open Access
Impact of BMI on CDK4/6 inhibitors efficacy and safety in advanced breast cancer: Results from a propensity score matched study—CAMELIA.
Journal of Clinical Oncology·2025
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
2025· 1 citedOpen Access
Author response: Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
2025Open Access
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
2025Open Access
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer
eLife·2025Open Access
Author response: Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
2025Open Access
Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: Results from a Propensity Score Matched Study (CAMELIA)
SSRN Electronic Journal·2025Open Access
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
2024Open Access
Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion
Translational Breast Cancer Research·2024· 1 citedOpen Access
Tyrosine kinase inhibitors in HER2‐positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real‐world study
MedComm·2024· 1 citedOpen Access
The war between the immune system and the tumor - using immune biomarkers as tracers
Biomarker Research·2024· 12 citedOpen Access
Abstract PO3-24-03: Cisplatin synergizes immune checkpoint blocking through RNFT1 mediated PD-L1 recycling in Triple Negative Breast Cancer
Cancer Research·2024
Abstract PO3-24-05: Cysteine metabolism related ferroptosis sensitivity in trastuzumab resistant HER2 positive breast cancer
Cancer Research·2024· 2 cited
Abstract PO4-04-06: Exploring the use of tyrosine kinase inhibitors (TKIs) in the management of HER2-positive metastatic breast cancer post trastuzumab emtansine (T-DM1) therapy failure: Insights from a real-world study
Cancer Research·2024
Abstract PO3-24-04: Altered epigenetic modifications and genome architecture reshape lipid metabolism during secondary trastuzumab resistance formation of HER2-positive breast cancer
Cancer Research·2024
page 1 of 3Next →

Frequent Co-authors

Yongmei Yin(40), Chunxiao Sun(34), Xiang Huang(25), Ziyi Fu(23), Tianyu Zeng(21), Ningjun Duan(19), Fan Yang(15), Yan Liang(14), Xueqi Yan(13), Jue Gong(11), Wěi Li(10), Min Tian(10), Mengzhu Yang(8), Yaozhou He(8), Shengnan Bao(8), Xinyu Wu(8), Yanting Sun(8), Shuhan Zhao(8), Qian Liu(7), Xiang Huang(6)